We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$8.4B
AUM Growth
+$1.66B
Cap. Flow
+$1.33B
Cap. Flow %
15.85%
Top 10 Hldgs %
61.33%
Holding
510
New
182
Increased
113
Reduced
52
Closed
146

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$79.7M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.4M
3
KVUE icon
Kenvue
KVUE
+$65.3M
4
ELF icon
e.l.f. Beauty
ELF
+$51.7M
5
GSK icon
GSK
GSK
+$46.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$96.3M
2
EXAS
Exact Sciences
EXAS
+$56.4M
3
PTCT icon
PTC Therapeutics
PTCT
+$34.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$28M
5
MDB icon
MongoDB
MDB
+$23M

Sector Composition

Rank Sector Weight
1 Healthcare 32.56%
2 Technology 5.44%
3 Consumer Discretionary 5.13%
4 Consumer Staples 2.69%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
51
Medtronic
MDT
$110B
$26.1M 0.31%
271,241
+5,984
+2% +$581K
GRFS
52
Grifois
GRFS
$5.41B
$25.9M 0.31%
2,768,000
+532,000
+24% +$4.84M
NKTR icon
53
Nektar Therapeutics
NKTR
$2.48B
$25.2M 0.3%
596,000
+328,000
+122% +$18.4M
NKE icon
54
Nike
NKE
$62B
$25.1M 0.3%
394,709
+315,616
+399% +$20.6M
PATH icon
55
UiPath
PATH
$7.17B
$25M 0.3%
1,524,617
+180,333
+13% +$2.81M
MLYS icon
56
Mineralys Therapeutics
MLYS
$2.38B
$24.5M 0.29%
676,035
+168,385
+33% +$6.75M
DHR icon
57
Danaher
DHR
$139B
$24.5M 0.29%
107,035
+75,477
+239% +$16.6M
EW icon
58
Edwards Lifesciences
EW
$52.1B
$23.7M 0.28%
277,478
+130,907
+89% +$10.7M
CVS icon
59
CVS Health
CVS
$125B
$23.5M 0.28%
295,589
+3,770
+1% +$297K
UBER icon
60
Uber
UBER
$138B
$23.1M 0.27%
282,734
+162,153
+134% +$14.6M
BCYC
61
Bicycle Therapeutics
BCYC
$279M
$22.9M 0.27%
3,236,000
+258,000
+9% +$1.9M
NBIS
62
Nebius Group N.V.
NBIS
$56.5B
$22.4M 0.27%
267,421
+54,141
+25% +$5.61M
ANGO icon
63
AngioDynamics
ANGO
$615M
$21.8M 0.26%
1,700,000
+64,000
+4% +$790K
DXCM icon
64
DexCom
DXCM
$31.6B
$21.4M 0.26%
+323,052
New +$20.9M
ARVN icon
65
Arvinas
ARVN
$552M
$21.3M 0.25%
1,800,000
+600,000
+50% +$6.55M
WYNN icon
66
Wynn Resorts
WYNN
$11.2B
$21.2M 0.25%
176,190
+59,246
+51% +$7.33M
MDB icon
67
MongoDB
MDB
$30.3B
$20.6M 0.25%
49,144
-63,255
-56% -$23M
ENR icon
68
Energizer
ENR
$1.51B
$20.6M 0.25%
+1,036,000
New +$22.6M
RH icon
69
RH
RH
$3.76B
$20.6M 0.25%
115,000
+24,315
+27% +$4.16M
WDAY icon
70
Workday
WDAY
$42.1B
$20.2M 0.24%
93,893
+33,001
+54% +$7.5M
BMY icon
71
Bristol-Myers Squibb
BMY
$131B
$20.1M 0.24%
372,466
-277,267
-43% -$13.3M
ROST icon
72
Ross Stores
ROST
$81.2B
$20M 0.24%
111,034
-104
-0.1% -$17.4K
IMVT icon
73
CALL
Immunovant
IMVT
$8.14B
$19.1M 0.23%
+750,000
New +$16.7M
HRMY icon
74
Harmony Biosciences
HRMY
$2.27B
$18.7M 0.22%
+500,000
New +$16.4M
HUM icon
75
Humana
HUM
$43.5B
$18.4M 0.22%
71,697
+20,338
+40% +$5.33M
1 2
3
4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return

Armistice Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Armistice Capital held 510 positions worth $8.4B, up 25% from $6.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Armistice Capital deployed $1.33B of net new capital in Q4 2025, opening 182 new positions and adding to 113 existing holdings. Its largest new stake was Kenvue: 3,992,196 shares worth $68.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $96.3M trimmed.

  • Armistice Capital's largest Q4 2025 buy was Kenvue: 3,992,196 shares worth $68.9M.
  • Armistice Capital added most to Agios Pharmaceuticals in Q4 2025, an estimated $79.7M increase.
  • Armistice Capital's biggest Q4 2025 reduction was Travere Therapeutics, cutting an estimated $96.3M.
  • Armistice Capital fully exited Exact Sciences in Q4 2025, selling an estimated $56.4M.
  • Armistice Capital's ten largest holdings make up 61% of its $8.4B portfolio in Q4 2025.
  • Armistice Capital opened 182 new positions and closed 146 in Q4 2025.
  • Armistice Capital's portfolio value rose 25% quarter-over-quarter to $8.4B.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.